Kratom, a Southeast Asian plant increasingly used for mood and pain relief, requires careful dosing and frequency to minimize risks. A recent overview from Yahoo Life highlights that low doses (1–5 grams) tend to produce stimulating effects, while higher amounts can lead to sedation and
Florida officials have expanded restrictions on 7-hydroxymitragynine (7-OH), a concentrated kratom-related compound, with a new emergency rule aimed at limiting its presence in consumer products. Attorney General James Uthmeier announced updated measures to close loopholes that allowed manufacturers to bypass earlier limits. Under the new rule,
The American Kratom Association (AKA) is pressing the American Medical Association (AMA) to draw a sharper line between traditional kratom leaf and newly emerging, chemically altered 7‑hydroxymitragynine (7‑OH) products. The group says that failing to distinguish between the two could mislead consumers and drive flawed
New York lawmakers have unanimously approved legislation to ban synthetic kratom products, targeting compounds like 7-hydroxymitragynine—an ուժlier, lab-enhanced chemical linked to addiction and overdose risks. If signed by Gov. Kathy Hochul, the state will join seven others in prohibiting these substances. Importantly, the bill does not ban natural
Nearly a year after the FDA drew a distinction between synthetic 7-hydroxymitragynine (7-OH) and natural kratom, federal policy remains absent, leaving states to adopt inconsistent regulations. According to a report by the American Kratom Association, scientists and policy experts will brief Congress on June 3
